For most providers especially those starting out or scaling thats a gamble
In October, a compounding industry group, the Outsourcing Facility Association, filed a lawsuit against the FDA's decision that there was no longer a shortage of tirzepatide, the active ingredient fin Zepbound and Mounjaro
10.1073/pnas.0606714103 116 WylieL
The first component, tirzepatide, is a dual GIP and GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves insulin sensitivity
Clarifying compoundgut microbiota interactions and whether microbial metabolism enhances or limits therapeutic efficacy would strengthen the gutliver axis perspective
Don't forget to follow us on LinkedIn for the latest updates